Neuralink Human Trial Expansion Updates: The Complete 2026 Guide

Key Questions & Expert Answers (Updated: 2026-03-08)

How many patients currently have a Neuralink implant?

As of March 2026, clinical data registries and corporate disclosures indicate there are currently 28 active patients living with a Neuralink device. This includes the initial feasibility cohort of 3 patients and an expanding pivotal trial cohort of 25 newly implanted individuals across the United States. This represents an over 800% increase in patient volume compared to early 2025.

Have the thread retraction issues from the first patient been fixed?

Yes. The early phenomenon where ultra-fine polymer threads retracted from the motor cortex—originally observed in the first patient, Noland Arbaugh—has been mitigated. The 2026 protocol utilizes the updated R1 Surgical Robot software, which embeds threads up to 2 millimeters deeper into the sulci of the brain. Combined with a modified "slack" mechanism in the polymer design, recent post-op MRI scans of the 2026 patient cohort show a 0% critical retraction rate.

Is the Blindsight device in human trials yet?

Yes. The FDA approved an Investigational Device Exemption (IDE) for Blindsight in Q4 2025. As of early 2026, two patients suffering from bilateral optic nerve damage have received the implant in their visual cortex. Preliminary stimulation tests are underway to map phosphene generation (perceiving flashes of light), though high-resolution structural vision is still years away.

1. The Evolution of the PRIME Study in 2026

The PRECISE Robotically Implanted Brain-Computer Interface (PRIME) study began as a highly conservative FDA-mandated Early Feasibility Study (EFS). The goal was singular: prove that a fully implantable, wireless BCI could safely allow a person with quadriplegia to control a computer cursor using only their thoughts. By early 2025, that milestone had been repeatedly verified.

Today, the landscape is vastly different. The FDA has permitted Neuralink to transition into an Early Pivotal Trial phase. Instead of operating solely out of a single surgical center, Neuralink has partnered with five major neurological research hospitals across the United States. This multi-center approach is critical for gathering generalized data required for eventual commercial approval.

Patients in the 2026 cohort are not just playing chess or controlling mice; they are utilizing advanced decoding algorithms that translate neural spikes into raw text at speeds approaching 45 words per minute, nearly matching average smartphone typing speeds. Furthermore, new endpoints have been added to the study, specifically focusing on digital accessibility tools for individuals with ALS (Amyotrophic Lateral Sclerosis) who suffer from locked-in syndrome.

2. Hardware Upgrades: Telepathy Gen 2

Much of the trial expansion has been facilitated by iterative hardware improvements. The original N1 implant (internally dubbed Telepathy Gen 1) was a marvel of miniaturization, but real-world human use revealed mechanical challenges. The brain pulsates with every heartbeat, and cerebrospinal fluid dynamics caused early shallow-inserted threads to pull out of the motor cortex.

The 2026 trials exclusively utilize the Telepathy Gen 2 architecture. While the external footprint of the coin-sized titanium enclosure remains identical (meaning it still fits flush with the skull invisibly), the microelectrode arrays have been redesigned.

• Variable Depth Insertion: The R1 robot now maps the patient's individual cortical topography via intraoperative ultrasound and targets varied depths, anchoring threads more securely beneath the pia mater.
• Thread Micro-Texturing: A newly patented bio-compatible coating promotes mild localized adhesion, preventing the threads from slipping over time while avoiding severe glial scarring.
• Enhanced Telemetry: Battery efficiency has been optimized, allowing patients up to 14 hours of continuous high-bandwidth use before needing to recharge via the specialized baseball-cap induction charger.

3. Blindsight: Restoring Vision Enters Phase 1

While the Telepathy implant targets the motor cortex (precentral gyrus) to restore digital agency, Neuralink's most ambitious project is Blindsight, which targets the visual cortex (occipital lobe). After receiving the FDA's Breakthrough Device Designation late in 2024, the medical community heavily anticipated human trials.

As of February 2026, those trials have begun. This represents a monumental leap in the complexity of the BCI. Unlike motor control, where the BCI "reads" brain activity, restoring vision requires the device to "write" information into the brain via micro-stimulation.

Early reports from the first two patients indicate successful elicitation of localized phosphenes. By stimulating specific electrodes, patients who have been totally blind for decades report seeing tiny flashes of light in specific areas of their visual field. The current challenge for the remainder of 2026 is refining the camera-to-cortex translation algorithm—essentially figuring out how to fire the electrodes in specific patterns that the brain can interpret as shapes, outlines, and eventually, low-resolution environmental awareness.

4. International Expansion: UK and Canada

To capture a broader demographic and navigate different regulatory environments, Neuralink has aggressively pursued international trial expansion in 2026. The United States FDA, while cooperative, moves at a cautious pace.

In a significant announcement earlier this year, the UK's Medicines and Healthcare products Regulatory Agency (MHRA) granted conditional approval for Neuralink to begin a parallel feasibility study in London. Similarly, Health Canada has approved a small cohort study targeting spinal cord bridging—a secondary research track aiming to bypass severed spinal cords by routing brain signals directly to limb stimulators.

These international moves are vital. Competitors like Synchron (which uses an endovascular stentrode) and Precision Neuroscience (which uses a surface-level film) have already been expanding their global footprints. Neuralink's international push ensures they maintain access to the best global research talent and diverse patient populations.

5. Future Outlook and Next Steps

Looking ahead to late 2026 and 2027, the primary objective for Neuralink is maintaining long-term safety data. The FDA typically requires 12 to 24 months of continuous safety data from a pivotal trial before considering a Pre-Market Approval (PMA) application, which would allow the device to be sold commercially to prescribed patients.

Furthermore, we can expect significant software updates. Since the neural decoding is processed externally on connected devices (like an iPad or PC), Neuralink has been integrating advanced generative AI models to predict user intent faster. This "smart autocomplete" for the brain reduces cognitive load on the patient, making the interface feel less like driving a manual car and more like natural, fluid thought.

If the current 28-patient cohort maintains high safety margins without severe adverse events (such as intracranial hemorrhage or unmanageable infections), we anticipate Neuralink will apply for a massive 100+ patient trial expansion by Q1 2027, marking the dawn of mainstream clinical neuro-prosthetics.

Frequently Asked Questions